← Back to all trials
Withdrawn
NCT03647891
Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized Cardiac Patients
Conditions: OSA, Heart Failure, Myocardial Infarction, Arrhythmia, Cardiac
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: Yes
Phase: NA
Sponsor: Kaiser Permanente
Location: Sleep Center; San Bernardino County Medical Center, Kaiser Permanente Fontana California
Summary
The purpose of this study is to determine whether early diagnosis of obstructive sleep apnea and initiation of and adherence to CPAP therapy in hospitalized cardiac patients would impact 30-day hospital readmission rates.
Eligibility Criteria
Inclusion Criteria:
* Kaiser Permanente member
* Males or female, any race, and age 18 and older
* OSA-predominant (AHI at or above 5) sleep disordered breathing
* Primary diagnosis upon admission of congestive heart failure, acute coronary syndrome, or arrhythmias
* Congestive heart failure (Acute or acute on chronic systolic heart failure, Acute or acute on chronic diastolic heart failure)
* Acute coronary syndrome (ST segment elevation myocardial infarction, Non-ST segment myocardial infarction, Unstable angina)
* Arrhythmias (Tachyarrhythmias, Atrial fibrillation, Atrial flutter, Bradyarrhythmias, Sinus bradycardia, 2nd degree atrioventricular block, Complete heart block)
* Appropriate to perform portable sleep study while on room air (no oxygen)
* Patients who are able and willing to give informed consent
Exclusion Criteria:
* Use of CPAP within 6 months of enrollment
* Patients with CSA-predominant sleep disordered breathing
* Patients who are "sleepy": ESS at or above 11
* Commercial driver's license or other occupational hazards (operating heavy machinery)
* Non-English speaking (validated questionnaires are currently limited to English)
* Patients with chronic respiratory failure requiring oxygen therapy or non-invasive ventilation.
* Patients requiring tracheostomy
* Pregnant patients
Source: ClinicalTrials.gov (NCT03647891). StuddyBuddy aggregates publicly available trial information.